Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Official title

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression

Study identification

NCT ID

NCT06767514

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Summit Therapeutics

Industry

Enrollment

780 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Feb 26, 2025

Primary completion

Mar 31, 2028

Completion

May 31, 2029

Last update posted

Jul 20, 2026

2025 – 2029

United States locations

U.S. sites

94

U.S. states

30

U.S. cities

86

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 176 non-U.S. sites.